Combination treatment of cardiovascular disease
Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.
1. A method of ameliorating the effects of congestive heart failure comprising: a) identifying a subject suffering from congestive heart failure b) harvesting CD34 + cells from umbilical cord blood mononuclear stem cells; c) intravenously injecting said CD34 + cells into said subject; d) intravenously administering mesenchymal stem cells to said subject and e) administering ascorbic acid or a derivative thereof intravenously to said subject to ameliorate the effects of congestive heart failure.
2. The method of claim 1 , wherein said ascorbic acid is administered intravenously in an amount of 15-700 g/week.
3. The method of claim 1 , wherein said ascorbic acid is administered intravenously in an amount of 25 g/day.
4. The method of claim 1 , wherein said ascorbic acid is intravenously administered to said subject prior to the administration of said CD34 + cells and mesenchymal stem cells.
5. The method of claim 1 , further comprising measuring oxidative stress in said subject prior to administration of said CD34 + cells and mesenchymal stem cells, and wherein the ascorbic acid is intravenously administrated at a concentration and frequency based upon said measurement of oxidative stress.
6. The method of claim 1 , wherein the subject is tested after being administered the ascorbic acid, CD34 + cells, and mesenchymal stem cells and there is an improvement in ejection fraction and clinical heart failure score.
7. The method of claim 1 , wherein the subject is tested after being administered the ascorbic acid, CD34 + cells, and mesenchymal stem cells and there is an improvement in ejection fraction.
8. The method of claim 1 , wherein the subject is tested after being administered the ascorbic acid, CD34 + cells, and mesenchymal stem cells and there is an improvement in clinical heart failure score.